RIVFLOZA Drug Patent Profile
✉ Email this page to a colleague
When do Rivfloza patents expire, and when can generic versions of Rivfloza launch?
Rivfloza is a drug marketed by Novo and is included in one NDA. There are six patents protecting this drug.
This drug has forty-one patent family members in seventeen countries.
The generic ingredient in RIVFLOZA is nedosiran sodium. One supplier is listed for this compound. Additional details are available on the nedosiran sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Rivfloza
Rivfloza will be eligible for patent challenges on September 29, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 29, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RIVFLOZA?
- What are the global sales for RIVFLOZA?
- What is Average Wholesale Price for RIVFLOZA?
Summary for RIVFLOZA
| International Patents: | 41 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in RIVFLOZA? | RIVFLOZA excipients list |
| DailyMed Link: | RIVFLOZA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RIVFLOZA
Generic Entry Date for RIVFLOZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INJECTION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for RIVFLOZA
RIVFLOZA is protected by six US patents and four FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RIVFLOZA is ⤷ Start Trial.
This potential generic entry date is based on patent 11,053,502.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-003 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-003 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-001 | Sep 29, 2023 | RX | Yes | Yes | 11,661,604 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-002 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-003 | Sep 29, 2023 | RX | Yes | Yes | 10,738,311 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-001 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-001 | Sep 29, 2023 | RX | Yes | Yes | 10,738,311 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RIVFLOZA
When does loss-of-exclusivity occur for RIVFLOZA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15330670
Estimated Expiration: ⤷ Start Trial
Patent: 21286295
Patent: Therapeutic Inhibition of Lactate Dehydrogenase and Agents Therefor
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 64168
Patent: INHIBITION THERAPEUTIQUE DE LA LACTATE-DESHYDROGENASE ET AGENTS ASSOCIES (THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR)
Estimated Expiration: ⤷ Start Trial
China
Patent: 7257858
Patent: 乳酸脱氢酶的治疗性抑制及其试剂 (Therapeutic inhibition of lactate dehydrogenase and agents therefor)
Estimated Expiration: ⤷ Start Trial
Denmark
Patent: 04497
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 04497
Patent: INHIBITION THÉRAPEUTIQUE DE LA LACTATE-DÉSHYDROGÉNASE ET AGENTS ASSOCIÉS (THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR)
Estimated Expiration: ⤷ Start Trial
Patent: 66896
Patent: INHIBITION THÉRAPEUTIQUE DE LA LACTATE-DÉSHYDROGÉNASE ET AGENTS ASSOCIÉS (THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR)
Estimated Expiration: ⤷ Start Trial
Hong Kong
Patent: 44300
Patent: 乳酸脫氫酶的治療性抑制及其試劑 (THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR)
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 1643
Patent: מעכב טיפולי של לקטאט דיהידרוגנאז וגורמים שלהם (Therapeutic inhibition of lactate dehydrogenase and agents therefor)
Estimated Expiration: ⤷ Start Trial
Patent: 5154
Patent: מעכב טיפולי של לקטאט דיהידרוגנאז וגורמים שלהם (Therapeutic inhibition of lactate dehydrogenase and agents therefor)
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 88292
Estimated Expiration: ⤷ Start Trial
Patent: 39539
Estimated Expiration: ⤷ Start Trial
Patent: 12318
Estimated Expiration: ⤷ Start Trial
Patent: 17532330
Patent: 乳酸デヒドロゲナーゼ及びその薬剤の治療的阻害
Estimated Expiration: ⤷ Start Trial
Patent: 20022493
Patent: 乳酸デヒドロゲナーゼ及びその薬剤の治療的阻害 (THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR)
Estimated Expiration: ⤷ Start Trial
Patent: 22091792
Patent: 乳酸デヒドロゲナーゼ及びその薬剤の治療的阻害
Estimated Expiration: ⤷ Start Trial
South Africa
Patent: 1703213
Patent: THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
Estimated Expiration: ⤷ Start Trial
Spain
Patent: 96923
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering RIVFLOZA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2015330670 | ⤷ Start Trial | |
| Australia | 2021286295 | ⤷ Start Trial | |
| Canada | 2964168 | ⤷ Start Trial | |
| China | 107257858 | ⤷ Start Trial | |
| Denmark | 3204497 | ⤷ Start Trial | |
| European Patent Office | 3204497 | ⤷ Start Trial | |
| European Patent Office | 3666896 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch